Structured page family:Cost guide
Triptorelin Cost Guide: Insurance, Cash Pay, and Savings
In the United States, Triptorelin costs depend on brand, pharmacy, insurance design, and whether the patient qualifies for manufacturer savings programs.
Active Market
This page is designed for US treatment decisions and uses US-first pricing and savings sources.
Official pricing
Verify current pricing directly on official Trelstar pages before starting, because list pricing, self-pay offers, and eligibility terms can change.
Cash-pay reality
Official cash-pay pricing varies by pharmacy and dose. Contact multiple pharmacies or use a prescription discount service for current rates.
Insurance coverage
Commercial coverage for Triptorelin varies by plan and indication. Prior authorization is commonly required.
Savings and coupons
Manufacturer savings programs may reduce out-of-pocket cost for eligible commercially insured patients.
Prior Authorization
Prior authorization is common and may require documentation of diagnosis, prior treatments, and clinical need.
Price Breakdown
List price (monthly)
~$1,500-$3,000/month depending on depot
Average wholesale price
~$1,400-$2,800/month
Pharmacy acquisition estimate
~$1,300-$2,500/month
Typical negotiated rate
~$1,000-$2,000/month
Price per dose
~$1,500 per 3.75 mg; ~$4,500 per 11.25 mg; ~$9,000 per 22.5 mg
Annual cost at list price
~$18,000-$36,000
Pharmacy Price Comparison
| Pharmacy | Price Range | Notes |
|---|---|---|
| Specialty pharmacy | $1,400-$3,000/month | Required |
| Hospital outpatient | Similar plus admin fee | May include injection fee |
Insurance Coverage Landscape
Commercial plans
~90-95% for oncology/gynecology indications
Medicare Part D
Covered; may be Part B
Medicaid
Covered for approved indications
VA coverage
On formulary
TRICARE
Covered
Employer plan typical tier
Tier 3-4; copay $50-150 or coinsurance 20-30%
Prior Authorization Guide
Required Documentation
- •Prostate cancer: pathology, staging
- •Endometriosis: surgical/laparoscopic confirmation
- •Precocious puberty: bone age, LH/FSH
Common Denial Reasons
- •Off-label use
- •Insufficient staging documentation
- •Not prescribed by specialist
Appeal Template Points
- •FDA-approved indication
- •Pathology confirmed
- •Specialist-prescribed
- •Standard of care
Expected timeline: 3-5 days
Savings Programs and Patient Assistance
Manufacturer PAP
manufacturerEligibility: Uninsured, ≤400% FPL
Savings: Free or reduced
Income limit: ≤400% FPL
Enrollment: moderate
Annual application
Copay card
copayEligibility: Commercially insured
Savings: May reduce significantly
Income limit: None
Enrollment: simple
Annual cap
Generic and Biosimilar Status
No generic currently available
Expected: No generic depot expected soon
Cost by Dose
| Dose/Regimen | Monthly | Annual |
|---|---|---|
| 3.75 mg monthly | $1,500 | $18,000 |
| 11.25 mg quarterly | $1,500 | $18,000 |
| 22.5 mg semi-annual | $1,500 | $18,000 |
Annual Cost Projection
Year 1
$1,200-$36,000
Year 2
$1,200-$36,000
Year 3
$1,200-$36,000
Assumptions
- •Ongoing therapy for prostate cancer
- •Interval affects total cost
Cost-Saving Strategies
- 1.Choose longer depot intervals (3 or 6 months) to reduce injection and admin costs
- 2.Apply for PAP if uninsured
- 3.Ensure specialist prescription for smoother prior auth
International Price Comparison
| Country | Price Range | Notes |
|---|---|---|
| UK | ~£300-600/month (~$380-760) | NHS |
Need help comparing triptorelin paths?
Use the provider matcher to package treatment interest, insurance, budget, urgency, and state context before you commit to a prescribing path.
Find a triptorelin providerNext Step
Use the cost calculator
Use provider matching when you need help comparing insured and self-pay treatment paths.
Open tool →Retention Path
Join the Triptorelin tracker waitlist
Capture refill timing, weekly dose history, and symptom notes in one planned workflow.
View tracker landing →Trust Summary
Reviewed 2026-04-27 by PeptideScholar editorial review. This page currently cites 2 official sources.
Pricing, savings eligibility, and coverage rules can change quickly. Verify all current figures and terms directly on official brand pages before acting.
Triptorelin Cost FAQ
Sources
- 1. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group.Eur Urol • 2014Claim type: clinicalView source →
- 2. FDA Information on TriptorelinFDA • 2026Claim type: regulatoryView source →
This content is for informational purposes only and does not constitute medical advice.